-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $141

Benzinga·12/12/2025 18:14:30
Listen to the news
Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $114 to $141.